Healthcare Sales & Marketing Network News: lupus

Searching News Database: lupus

HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Dec 2021
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals

HSMN NewsFeed - 26 Aug 2021
FDA Clears Thermo Scientific EliA SmD(P)-S Test For Use In U.S.
Diagnostics FDA

HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 8 Apr 2021
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jan 2021
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Nov 2020
Athos Therapeutics Announces Appointment of Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Aug 2020
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jun 2020
SFA Therapeutics Announces FDA Approval To Begin IND Trial
Biopharmaceuticals Dermatology

HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 29 Apr 2020
ANI Receives Refusal to File Letter from FDA for Cortrophin(R) Gel
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Apr 2020
Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Mar 2020
DxTerity Receives CE Mark for DxCollect(R) Fingerstick Blood RNA Stabilization Device
Devices Diagnostics Regulatory

HSMN NewsFeed - 27 Jan 2020
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Jan 2020
Provention Bio Appoints Jason Hoitt as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Oct 2019
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Oct 2019
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 22 Apr 2019
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Biopharmaceuticals Licensing

HSMN NewsFeed - 2 Apr 2019
Provention Bio Announces Key Additions to its Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 31 Aug 2018
Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Biopharmaceuticals

HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 8 Mar 2018
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 7 Mar 2018
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
Diagnostics Product Launch

HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch

HSMN NewsFeed - 28 Sep 2017
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Biopharmaceuticals Generics Litigation Licensing

HSMN NewsFeed - 25 Aug 2017
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Jul 2017
Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Jul 2017
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Apr 2017
MENTOR(R) Launches MENTORPromise Protection Plan
Devices Product Launch

HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Apr 2017
U.S. FDA Issues Complete Response Letter for Baricitinib
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Feb 2017
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Jan 2017
Celgene to Acquire Delinia, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Dec 2016
Neovacs obtains FDA �Fast Track� designation for IFNα Kinoid in Lupus (SLE)
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 18 Oct 2016
Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Jun 2016
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
Biopharmaceuticals Neurology

HSMN NewsFeed - 7 Mar 2016
Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jan 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Regulatory

HSMN NewsFeed - 4 Jan 2016
Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Sep 2015
Audentes Therapeutics Expands Senior Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Sep 2015
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 16 Jun 2015
Kezar Life Sciences Closes $23M Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 27 Feb 2015
FDA Approves Allergan�s NATRELLE INSPIRA(TM) Round Gel-Filled Breast Implants
Devices FDA

HSMN NewsFeed - 2 Oct 2014
Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies
Biopharmaceuticals

HSMN NewsFeed - 13 Aug 2014
Inotek Pharmaceuticals Names David P. Southwell as President and Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 28 Jul 2014
Aqua Pharmaceuticals, LLC Announces the U.S. Food and Drug Administration (FDA) Approval of ACTICLATE(TM) (doxycycline hyclate USP) Tablets, 150 mg and 75 mg
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Apr 2014
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 11 Mar 2014
Caisson Biotech Expands HEPtune(TM) Drug Delivery Deal with Novo Nordisk
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 6 Nov 2013
Aurinia Appoints Accomplished Biotech and Pharma Industry Veteran, Stephen W. Zaruby, as President & CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Oct 2013
Exagen Diagnostics Appoints New Board Member
Diagnostics Personnel

HSMN NewsFeed - 24 Oct 2013
Rigel Provides Pipeline Update
Biopharmaceuticals

HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Sep 2013
ImmusanT Names Ferdinand E. Massari as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jul 2013
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2013
Questcor Pharmaceuticals Acquires Rights to Synacthen(R)
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 20 Feb 2013
FDA Approves Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Devices FDA

HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Dec 2012
Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 12 Nov 2012
Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals

HSMN NewsFeed - 1 Nov 2012
Resolve Therapeutics Raises $5.8 Million in Private Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Oct 2012
Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA(R) (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 1 Oct 2012
XDx Appoints Peter Maag as President and CEO
Diagnostics Personnel

HSMN NewsFeed - 19 Jun 2012
AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
Abbott Announces 10-Year Data Evaluating HUMIRA(R) (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2011
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2011
Abbott Presents HUMIRA(R) (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2011
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA(R) (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Biopharmaceuticals

HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Jun 2011
Sheila Gujrathi, M.D. Named Chief Medical Officer of Receptos
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 May 2011
GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 May 2011
Resolve Announces Series A Financing, New Board Members
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals

HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 7 Dec 2010
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Nov 2010
New Data on H.P. Acthar(R) Gel in the Treatment of Nephrotic Syndrome Presented at the American Society of Nephrology 43rd Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 22 Nov 2010
Interim Results From Independent Study of H.P. Acthar(R) Gel in Patients With Advanced Diabetic Nephropathy Presented at American Society of Nephrology 43rd Annual Meeting
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 3 Nov 2010
Questcor Pharmaceuticals Launches Acthar for the Treatment of Infantile Spasms
Biopharmaceuticals

HSMN NewsFeed - 15 Oct 2010
FDA Approves H.P. Acthar(R) Gel for the Treatment of Infantile Spasms
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 5 Oct 2010
NKT Therapeutics Announces Hiring of Barbara Finck, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Sep 2010
La Jolla Pharmaceutical Company Provides Update on Search for Clinical Products to In-License or Acquire
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Aug 2010
Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI(R) (epoprostenol for injection) for Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Aug 2010
Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA(R) (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Aug 2010
Human Genome Sciences Names Tuomo P�tsi Vice President, HGS Europe
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jun 2010
New Data Presented from EMBLEM Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 10 Jun 2010
Human Genome Sciences Announces Submission of Biologics License Application to FDA for BENLYSTA(R) (belimumab)
Biopharmaceuticals

HSMN NewsFeed - 7 Jun 2010
Human Genome Sciences Announces Submission of Marketing Authorization Application to EMA for BENLYSTA(R) (Belimumab)
Biopharmaceuticals

HSMN NewsFeed - 19 May 2010
Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 22 Apr 2010
Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals

HSMN NewsFeed - 20 Apr 2010
Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 19 Apr 2010
Human Genome Sciences Announces Withdrawal of European Marketing Authorization Application For JOULFERON(R) (ZALBIN) For the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 9 Mar 2010
Human Genome Sciences Appoints David P. Southwell Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Feb 2010
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 1 Feb 2010
Human Genome Sciences Names Scott Habig Vice President, Sales
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Dec 2009
FDA Accepts for Review Questcor's Filing of Its Supplemental New Drug Application for H.P. Acthar(R) Gel for Treatment of Infantile Spasms
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2009
Louis Silverman Appointed to Questcor Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Dec 2009
Adamis Pharmaceuticals Announces Signing of Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Dec 2009
La Jolla Pharmaceutical Company Announces Signing of Definitive Merger Agreement With Adamis Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Nov 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 20 Oct 2009
Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 9 Oct 2009
Lycera Appoints Key Executives to Drug Development Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Aug 2009
XDx Completes $14.4 Million Series G Financing
Diagnostics Venture Capital

HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Jul 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 19 May 2009
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals

HSMN NewsFeed - 25 Apr 2009
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Apr 2009
Lycera Closes $36 Million Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Mar 2009
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Feb 2009
Opsona Therapeutics Closes EUR18M Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Feb 2009
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2009
La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial
Biopharmaceuticals

HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 26 Jan 2009
Sequenom Expands Molecular Diagnostics Portfolio with Acquisition of SensiGen
Diagnostics Acquisitions

HSMN NewsFeed - 6 Jan 2009
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Biopharmaceuticals

HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Biopharmaceuticals Neurology

HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals

HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals

HSMN NewsFeed - 21 May 2008
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 15 May 2008
Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals

HSMN NewsFeed - 6 May 2008
REGiMMUNE Raises $8,000,000 in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2008
Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
Diagnostics FDA

HSMN NewsFeed - 31 Mar 2008
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Biopharmaceuticals Cardiology

HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Mar 2008
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Program; Announces Fourth Quarter and Year-End 2007 Financial Results
Biopharmaceuticals

HSMN NewsFeed - 7 Mar 2008
In Post-Vioxx Era, Biologics Are Reviving Arthritis Treatment Market
Biopharmaceuticals

HSMN NewsFeed - 25 Feb 2008
Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
Diagnostics

HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Feb 2008
Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Feb 2008
Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
Biopharmaceuticals

HSMN NewsFeed - 13 Feb 2008
VLST Corporation Announces Board and Executive Management Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Feb 2008
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
Biopharmaceuticals

HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals

HSMN NewsFeed - 18 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2008
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
Biopharmaceuticals Licensing

HSMN NewsFeed - 26 Dec 2007
Dr. Robert Karr Resigns from Management Position at Idera
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Dec 2007
Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Biopharmaceuticals Licensing

HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals

HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Nov 2007
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve BP Goals
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 19 Nov 2007
Genelabs Technologies Regains Exclusive Rights to Prestara(TM) in Japan From Mitsubishi Tanabe Pharma Corporation
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2007
Argos Therapeutics and Therakos, Inc. Enter Exclusive Agreement for Regulatory T Cell Technology
Biopharmaceuticals Licensing

HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Nov 2007
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2007
Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals

HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2007
GlaxoSmithKline and Tolerx Form Worldwide Collaboration for Development and Commercialization of Novel Medication
Biopharmaceuticals

HSMN NewsFeed - 4 Oct 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Sep 2007
Teva Provides Update on Edratide for Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2007
FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Sep 2007
VLST Corp Names Consuelo M. Blosch, M.D., Vice President of Clinical and Regulatory and Dan Allison, Ph.D., Sr. Director of Therapeutic Design
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Sep 2007
Aspreva Provides Update On Lupus Nephritis Development Program
Biopharmaceuticals

HSMN NewsFeed - 5 Sep 2007
Bar Harbor BioTechnology Inc. Completes Series A Financing for Product Launch
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 30 Aug 2007
Competitive Technologies Obtains License Rights to Innovative Surgical Device
Devices Licensing

HSMN NewsFeed - 28 Aug 2007
Aspreva and Roche Update CellCept Agreement
Biopharmaceuticals

HSMN NewsFeed - 6 Aug 2007
Immunomedics Appoints Edward T. Wolynic to Board Of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 30 Jul 2007
Corgenix Submits 510(k) Filing for IgG Anti-AtherOx(TM) Test Kit
Diagnostics FDA

HSMN NewsFeed - 25 Jul 2007
Aspreva announces restructuring designed to drive long-term growth
Biopharmaceuticals

HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Biopharmaceuticals

HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Jun 2007
Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jun 2007
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2007
Bosentan (Tracleer) Receives EU Approval for Reduction of Number of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Jun 2007
Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon(R)
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Jun 2007
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 24 May 2007
La Jolla Pharmaceutical Company Reports Riquent(R) Well Tolerated in Three Studies at International Lupus Congress
Biopharmaceuticals

HSMN NewsFeed - 22 May 2007
New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology

HSMN NewsFeed - 14 May 2007
Bayhill Therapeutics Appoints Fred Kurland as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2007
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 May 2007
Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R) (Adalimumab) as a Treatment for Juvenile Rheumatoid Arthritis
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2007
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Biopharmaceuticals

HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 4 Apr 2007
The Immune Response Corporation Announces Rebranding to Reflect Expanded Focus on Treatment of Autoimmune Diseases
Biopharmaceuticals

HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 26 Mar 2007
Bosentan -- Tracleer -- Receives Positive EU Opinion for Reduction of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals

HSMN NewsFeed - 20 Mar 2007
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals

HSMN NewsFeed - 8 Mar 2007
Astion Pharma Prepares Management Structure for Bringing Pharmaceuticals to Market
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Mar 2007
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Announces Positive Interim Results of Phase 2b Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 13 Feb 2007
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 7 Feb 2007
NeoStem, Inc. Appoints Wayne A. Marasco, M.D., Ph.D., to Chair Company's Scientific Advisory Board
Regenerative Medicine Personnel

HSMN NewsFeed - 1 Feb 2007
La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent(R) Study
Biopharmaceuticals

HSMN NewsFeed - 12 Jan 2007
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2006
NeoStem Announces Five-Year Agreement With HemaCare for Adult Stem Cell Collection Services
Regenerative Medicine

HSMN NewsFeed - 19 Dec 2006
Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 19 Dec 2006
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 18 Dec 2006
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
Biopharmaceuticals

HSMN NewsFeed - 11 Dec 2006
NeoStem, Inc. Appoints Prominent Authority in Hematologic Oncology to the Company's Scientific Advisory Board
Regenerative Medicine Personnel

HSMN NewsFeed - 4 Dec 2006
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2006
Bayhill Therapeutics Names Paul Westberg Vice President of Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Nov 2006
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 15 Nov 2006
Bayhill Therapeutics Names Robert S. King Vice President of Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Nov 2006
FDA Allows Resumption of Lupus Trials with Epratuzumab
Biopharmaceuticals

HSMN NewsFeed - 14 Nov 2006
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
Epratuzumab and Rituximab Have Different Modes of Action
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2006
NeoStem, Inc. Appoints Prominent Authority in Cardiology and Stem Cell Research to the Company's Advisory Board
Regenerative Medicine Personnel

HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
Biopharmaceuticals

HSMN NewsFeed - 31 Oct 2006
Gene Expression Test From XDx Now Indicated for Earlier Use and Prediction of Acute Cellular Rejection
Diagnostics Cardiology Reimbursement

HSMN NewsFeed - 31 Oct 2006
Human Genome Sciences Reports Positive Interim Results of Phase 2 Trials of Albuferon(TM) With Ribavirin in Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals

HSMN NewsFeed - 26 Oct 2006
NeoStem, Inc. Appoints Julio C. Guerra, MD, ABP, as Director of Sales and Marketing
Regenerative Medicine Personnel

HSMN NewsFeed - 26 Oct 2006
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Oct 2006
New Analysis Shows CIMZIA(TM) (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 23 Oct 2006
New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 16 Oct 2006
Human Genome Sciences Reports Positive Interim Quality-of-Life Data From Phase 2B Trial of Albuferon(TM) with Ribavirin in Treatment-Naive Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 12 Oct 2006
La Jolla Pharmaceutical Provides Update on MAA Application in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals

HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Announces Phase 3 Clinical Development Program for Albuferon(TM) in Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2006
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
Biopharmaceuticals

HSMN NewsFeed - 28 Aug 2006
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Aug 2006
Genelabs Names Peter R. Young, Ph.D. as Vice President, Biology and Announces Resignation of Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Aug 2006
Phase III Medical Appoints Director of Stem Cell Banking and Clinical Applications
Regenerative Medicine Personnel

HSMN NewsFeed - 16 Aug 2006
XDx Announces Appointment of Dr. James Yee as Chief Medical Officer
Diagnostics Personnel

HSMN NewsFeed - 9 Aug 2006
La Jolla Pharmaceutical Expands Enrollment in Phase 3 International Riquent(R) Study
Biopharmaceuticals

HSMN NewsFeed - 9 Aug 2006
Human Genome Sciences Announces Phase 3 Clinical Development Program for LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 17 Jul 2006
Michael Tansey, M.D. Joins La Jolla Pharmaceutical Company as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2006
CoTherix Licenses Exclusive Rights to Develop and Commercialize Oral and Inhaled Formulations of Fasudil for the Treatment of PAH and Stable Angina in North America and Europe From Asahi Kasei Pharma
Biopharmaceuticals Licensing

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 22 Jun 2006
La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Jun 2006
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 16 Jun 2006
VLST Corporation Raises $55 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 2 Jun 2006
Repeated Radioimmunotherapy With 131I-Labetuzumab in Colorectal Cancer With Liver Metastases Found Safe and Well-Tolerated in Initial Phase II Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 19 May 2006
Diovan(R) (valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
Biopharmaceuticals Licensing

HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Biopharmaceuticals Licensing

HSMN NewsFeed - 1 May 2006
FDA Approves Higher Dose Formulations of Diovan HCT(R) (valsartan/hydrochlorothiazide) for Treatment of High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Apr 2006
PEGASYS(R) ACCELERATE Trial Shows Six Months of Treatment Is Optimal for Achieving Success in Category of Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 29 Apr 2006
New Oral Polymerase Inhibitor Shows Promising Results in Chronic Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 26 Apr 2006
EU Label Change for INTRON(R) A (interferon Alfa-2b) Incorporates Long-Term Efficacy Data in Patients with Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 24 Apr 2006
Epratuzumab for Immunotherapy of Lupus Results Published
Biopharmaceuticals

HSMN NewsFeed - 30 Mar 2006
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan(R) in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Mar 2006
La Jolla Pharmaceutical Announces Appointment of Deirdre Y. Gillespie as New Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Mar 2006
African American Heart Failure Trial Shows Women and Men Both Benefit from BiDil(R)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 13 Mar 2006
Researchers Identify Gene Variations That May Determine Which Heart Failure Patients Are Likely to Benefit from Treatment With BiDil(R)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Feb 2006
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Feb 2006
TolerRx Receives Orphan Drug Designation from FDA for TRX4 for the Treatment of New-Onset Type 1 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 30 Jan 2006
Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Jan 2006
Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Jan 2006
VLST Corporation and Accelerator Corporation Name Martin A. Simonetti President and Chief Executive Officer of VLST
Biopharmaceuticals Personnel

Return to NewsFeed

Additional items found! 136

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 136 additional stories matching:
lupus
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.